BridgeBio revenue exceeds expectations but losses widen, stock price rises

LootboxPhobia · 2026-02-25T10:53:29+00:00

BridgeBio Pharma Inc. announced fourth-quarter revenue of $154.2 million, beating expectations, despite a per-share loss of $1.00, which was higher than anticipated. Its drug Attruby contributed significantly, with revenue increasing substantially. Additionally, the company reported positive results from three Phase III clinical trials and plans to submit new drug applications.

LootboxPhobia

2026-02-25 10:53:29

Abstract generation in progress

Investing.com – BridgeBio Pharma Inc. (NASDAQ: BBIO) announced fourth-quarter revenue of $154.2 million, exceeding analysts’ expectations of $146.16 million, despite reporting a larger-than-expected loss. The biopharmaceutical company reported an adjusted loss of $1.00 per share, compared to the market consensus of a $0.72 loss per share.

Revenue surged from $5.9 million in the same period last year, mainly driven by net product revenue of $146 million from its treatment for transthyretin amyloid cardiomyopathy drug Attruby. As of February 20, 2026, since receiving FDA approval in November 2024, 1,856 prescribing physicians have issued 7,804 unique patient prescriptions. The stock rose 3.4% in after-hours trading on Tuesday.

Co-founder and CEO Neil Kumar stated, “In just over three months, we delivered three successful Phase 3 clinical trial results, demonstrating our scientific rigor, team dedication, and the trust of the patients and doctors we serve.”

Full-year 2025 revenue reached $502.1 million, up from $221.9 million in 2024, with net product revenue of $362.4 million. Attruby’s net product revenue in the fourth quarter grew 35% quarter-over-quarter.

The company has announced three positive Phase 3 trial results in recent months. The FORTIFY trial for BBP-418 targeting LGMD2I/R9 met all primary and secondary endpoints. BridgeBio plans to submit an NDA in the first half of 2026 and expects to launch in the U.S. by late 2026 or early 2027. The CALIBRATE trial for encaleret targeting ADH1 also achieved all efficacy endpoints, with a similar submission and launch timeline. The PROPEL 3 trial for oral infigratinib for achondroplasia met its primary endpoint, with plans to submit an NDA in the second half of 2026.

As of December 31, 2025, BridgeBio held $587.5 million in cash, cash equivalents, and marketable securities. The company completed a $632.5 million convertible bond issuance in January 2026.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes